10-Q 1 veru-20240331x10q.htm 10-Q veru-20240331x10q
falseQ220240000863894YesYesP10Y0000863894srt:MaximumMemberveru:LincolnParkPurchaseAgreementMember2023-12-132023-12-130000863894veru:MaximumSharePurchaseStockPriceRangeThreeMemberveru:LincolnParkPurchaseAgreementMember2023-12-132023-12-130000863894veru:MaximumSharePurchaseStockPriceRangeOneMemberveru:LincolnParkPurchaseAgreementMember2023-12-132023-12-130000863894veru:MaximumSharePurchaseStockPriceRangeThreeMemberveru:LincolnParkPurchaseAgreementMember2023-12-130000863894veru:MaximumSharePurchaseStockPriceRangeOneMemberveru:LincolnParkPurchaseAgreementMember2023-12-130000863894srt:MaximumMemberveru:LincolnParkPurchaseAgreementMember2023-12-130000863894veru:LincolnParkPurchaseAgreementMember2023-12-120000863894veru:LincolnParkPurchaseAgreementMember2023-12-132023-12-130000863894veru:LincolnParkPurchaseAgreementMember2023-12-130000863894veru:JefferiesSalesAgreementMember2023-05-122023-05-1200008638942023-03-012023-03-310000863894veru:PayableInEqualMonthlyInstallmentsOver48MonthsMemberveru:CommercialDisputeMember2024-02-292024-02-290000863894veru:AllOrPortionOutstandingAsOfDecember312025Memberveru:CommercialDisputeMember2024-02-292024-02-290000863894us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-03-310000863894veru:CurrentAccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-10-012024-03-310000863894us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-10-012024-03-310000863894us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-10-012024-03-310000863894us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-03-310000863894veru:CurrentAccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2022-10-012023-09-300000863894us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2022-10-012023-09-300000863894us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-10-012023-03-310000863894srt:MinimumMemberveru:EstimatedChangeOfControlDatesMember2023-10-012024-03-310000863894srt:MaximumMemberveru:EstimatedChangeOfControlDatesMember2023-10-012024-03-310000863894srt:MinimumMemberveru:EstimatedChangeOfControlDatesMember2022-10-012023-09-300000863894srt:MaximumMemberveru:EstimatedChangeOfControlDatesMember2022-10-012023-09-300000863894veru:EntadfiMemberus-gaap:SubsequentEventMember2024-04-242024-04-240000863894veru:PayableOnSeptember302024Memberveru:EntadfiMemberus-gaap:SubsequentEventMember2024-04-240000863894veru:PayableOnApril292024Memberveru:EntadfiMemberus-gaap:SubsequentEventMember2024-04-240000863894srt:ScenarioForecastMemberveru:EntadfiMember2024-04-190000863894veru:EntadfiMember2023-09-290000863894srt:ScenarioForecastMemberveru:EntadfiMember2024-09-300000863894veru:PremiumFinanceAgreementMember2022-11-012022-11-010000863894veru:ResidualRoyaltyAgreementMember2023-10-012024-03-310000863894srt:MinimumMember2023-10-012024-03-310000863894srt:MaximumMember2023-10-012024-03-310000863894country:BR2023-10-012024-03-310000863894us-gaap:AdditionalPaidInCapitalMember2022-10-012022-12-310000863894us-gaap:AdditionalPaidInCapitalMemberveru:PublicOfferingMember2023-10-012023-12-310000863894us-gaap:AdditionalPaidInCapitalMemberveru:LincolnParkAndAspireCapitalPurchaseAgreementsMember2023-10-012023-12-310000863894us-gaap:AdditionalPaidInCapitalMemberveru:JefferiesSalesAgreementMember2023-10-012023-12-310000863894veru:PublicOfferingMember2023-10-012023-12-310000863894veru:LincolnParkAndAspireCapitalPurchaseAgreementsMember2023-10-012023-12-310000863894veru:JefferiesSalesAgreementMember2023-10-012023-12-310000863894us-gaap:CommonStockMember2022-10-012022-12-310000863894us-gaap:CommonStockMemberveru:PublicOfferingMember2023-10-012023-12-310000863894us-gaap:CommonStockMemberveru:LincolnParkAndAspireCapitalPurchaseAgreementsMember2023-10-012023-12-310000863894us-gaap:CommonStockMemberveru:JefferiesSalesAgreementMember2023-10-012023-12-310000863894us-gaap:CommonStockMember2023-01-012023-03-310000863894veru:LincolnParkPurchaseAgreementMember2023-05-022023-05-020000863894us-gaap:TreasuryStockCommonMember2024-03-310000863894us-gaap:RetainedEarningsMember2024-03-310000863894us-gaap:AdditionalPaidInCapitalMember2024-03-310000863894us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310000863894us-gaap:TreasuryStockCommonMember2023-12-310000863894us-gaap:RetainedEarningsMember2023-12-310000863894us-gaap:AdditionalPaidInCapitalMember2023-12-310000863894us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-3100008638942023-12-310000863894us-gaap:TreasuryStockCommonMember2023-09-300000863894us-gaap:RetainedEarningsMember2023-09-300000863894us-gaap:AdditionalPaidInCapitalMember2023-09-300000863894us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300000863894us-gaap:TreasuryStockCommonMember2023-03-310000863894us-gaap:RetainedEarningsMember2023-03-310000863894us-gaap:AdditionalPaidInCapitalMember2023-03-310000863894us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310000863894us-gaap:TreasuryStockCommonMember2022-12-310000863894us-gaap:RetainedEarningsMember2022-12-310000863894us-gaap:AdditionalPaidInCapitalMember2022-12-310000863894us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-3100008638942022-12-310000863894us-gaap:TreasuryStockCommonMember2022-09-300000863894us-gaap:RetainedEarningsMember2022-09-300000863894us-gaap:AdditionalPaidInCapitalMember2022-09-300000863894us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300000863894us-gaap:CommonStockMember2024-03-310000863894us-gaap:CommonStockMember2023-12-310000863894us-gaap:CommonStockMember2023-09-300000863894us-gaap:CommonStockMember2023-03-310000863894us-gaap:CommonStockMember2022-12-310000863894us-gaap:CommonStockMember2022-09-300000863894veru:PublicOfferingMember2023-12-180000863894us-gaap:StockAppreciationRightsSARSMember2024-03-310000863894us-gaap:StockAppreciationRightsSARSMember2018-10-310000863894veru:EmployeeMemberus-gaap:StockAppreciationRightsSARSMember2018-10-312018-10-310000863894srt:DirectorMemberus-gaap:StockAppreciationRightsSARSMember2018-10-312018-10-310000863894us-gaap:EmployeeStockOptionMember2023-09-300000863894veru:TwoThousandAndSeventeenEquityIncentivePlanMember2024-03-310000863894veru:TwoThousandEightStockIncentivePlanMember2024-03-310000863894veru:TwentyEighteenEquityIncentivePlanMember2024-03-310000863894veru:InducementPlan2022Member2024-03-310000863894veru:TwoThousandAndSeventeenEquityIncentivePlanMember2017-07-310000863894srt:MaximumMemberus-gaap:EmployeeStockOptionMember2023-10-012024-03-310000863894us-gaap:StockAppreciationRightsSARSMember2018-10-312018-10-310000863894veru:BlueWaterVaccinesIncMemberveru:EntadfiMemberus-gaap:PreferredStockMember2023-10-032023-10-030000863894veru:OtherCountriesMember2024-01-012024-03-310000863894veru:Fc2U.s.PrescriptionChannelMember2024-01-012024-03-310000863894veru:Fc2ProductsMember2024-01-012024-03-310000863894veru:Fc2GlobalPublicHealthSectorMember2024-01-012024-03-310000863894country:ZA2024-01-012024-03-310000863894country:US2024-01-012024-03-310000863894country:MZ2024-01-012024-03-310000863894veru:OtherCountriesMember2023-10-012024-03-310000863894veru:Fc2U.s.PrescriptionChannelMember2023-10-012024-03-310000863894veru:Fc2ProductsMember2023-10-012024-03-310000863894veru:Fc2GlobalPublicHealthSectorMember2023-10-012024-03-310000863894country:ZA2023-10-012024-03-310000863894country:US2023-10-012024-03-310000863894country:MZ2023-10-012024-03-310000863894veru:OtherCountriesMember2023-01-012023-03-310000863894veru:Fc2U.s.PrescriptionChannelMember2023-01-012023-03-310000863894veru:Fc2ProductsMember2023-01-012023-03-310000863894veru:Fc2GlobalPublicHealthSectorMember2023-01-012023-03-310000863894veru:EntadfiMember2023-01-012023-03-310000863894country:ZA2023-01-012023-03-310000863894country:US2023-01-012023-03-310000863894veru:OtherCountriesMember2022-10-012023-03-310000863894veru:Fc2U.s.PrescriptionChannelMember2022-10-012023-03-310000863894veru:Fc2ProductsMember2022-10-012023-03-310000863894veru:Fc2GlobalPublicHealthSectorMember2022-10-012023-03-310000863894veru:EntadfiMember2022-10-012023-03-310000863894country:ZA2022-10-012023-03-310000863894country:US2022-10-012023-03-310000863894srt:RestatementAdjustmentMemberveru:CommercialDisputeMember2024-01-012024-03-310000863894srt:RestatementAdjustmentMemberveru:CommercialDisputeMember2023-10-012024-03-310000863894veru:ResidualRoyaltyAgreementMember2018-03-052021-08-310000863894srt:MinimumMemberveru:EquipmentFurnitureAndFixturesMember2024-03-310000863894srt:MinimumMemberus-gaap:MachineryAndEquipmentMember2024-03-310000863894srt:MinimumMemberus-gaap:LeaseholdImprovementsMember2024-03-310000863894srt:MaximumMemberveru:EquipmentFurnitureAndFixturesMember2024-03-310000863894srt:MaximumMemberus-gaap:MachineryAndEquipmentMember2024-03-310000863894srt:MaximumMemberus-gaap:LeaseholdImprovementsMember2024-03-310000863894veru:EquipmentFurnitureAndFixturesMember2024-03-310000863894us-gaap:MachineryAndEquipmentMember2024-03-310000863894us-gaap:LeaseholdImprovementsMember2024-03-310000863894veru:EquipmentFurnitureAndFixturesMember2023-09-300000863894us-gaap:MachineryAndEquipmentMember2023-09-300000863894us-gaap:LeaseholdImprovementsMember2023-09-300000863894veru:EntadfiMember2023-09-292023-09-290000863894veru:EntadfiMember2023-04-192023-04-190000863894veru:SwkCreditAgreementMember2018-03-052018-03-050000863894veru:PublicOfferingMember2023-12-182023-12-180000863894veru:PublicOfferingMember2023-10-012024-03-310000863894veru:LincolnParkAndAspireCapitalPurchaseAgreementsMember2023-10-012024-03-310000863894veru:JefferiesSalesAgreementMember2023-10-012024-03-310000863894veru:JefferiesSalesAgreementMember2023-05-122024-03-310000863894veru:LincolnParkPurchaseAgreementMember2023-05-022024-03-310000863894veru:LincolnParkAndAspireCapitalPurchaseAgreementsMember2022-10-012023-03-310000863894veru:PreferredClassSeries4Member2024-03-310000863894veru:PreferredClassASeries3Member2024-03-310000863894veru:PreferredClassASeries2Member2024-03-310000863894veru:PreferredClassASeries1Member2024-03-310000863894veru:PreferredClassSeries4Member2023-09-300000863894veru:PreferredClassASeries3Member2023-09-300000863894veru:PreferredClassASeries2Member2023-09-300000863894veru:PreferredClassASeries1Member2023-09-300000863894us-gaap:PreferredClassBMember2024-03-310000863894us-gaap:PreferredClassAMember2024-03-310000863894veru:BlueWaterVaccinesIncMemberveru:EntadfiMemberus-gaap:PreferredStockMember2023-10-030000863894us-gaap:PreferredClassBMember2023-09-300000863894us-gaap:PreferredClassAMember2023-09-300000863894veru:BlueWaterVaccinesIncMemberveru:EntadfiMemberus-gaap:CommonStockMember2023-10-030000863894us-gaap:RetainedEarningsMember2024-01-012024-03-310000863894us-gaap:RetainedEarningsMember2023-10-012023-12-310000863894us-gaap:RetainedEarningsMember2023-01-012023-03-310000863894us-gaap:RetainedEarningsMember2022-10-012022-12-3100008638942022-10-012022-12-310000863894veru:PremiumFinanceAgreementMember2024-03-310000863894veru:PremiumFinanceAgreementMember2023-09-300000863894veru:MeasurementInputProbabilityOfDissolutionMember2024-03-310000863894us-gaap:MeasurementInputPriceVolatilityMember2024-03-310000863894us-gaap:MeasurementInputExpectedTermMember2024-03-310000863894us-gaap:MeasurementInputDiscountRateMember2024-03-310000863894us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember2024-03-310000863894veru:MeasurementInputProbabilityOfDissolutionMember2023-10-030000863894us-gaap:MeasurementInputPriceVolatilityMember2023-10-030000863894us-gaap:MeasurementInputExpectedTermMember2023-10-030000863894us-gaap:MeasurementInputDiscountRateMember2023-10-030000863894us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember2023-10-030000863894us-gaap:EmployeeStockOptionMember2024-03-310000863894srt:MinimumMemberveru:MeasurementInputProbabilityOfChangeOfControlMember2024-03-310000863894srt:MinimumMemberus-gaap:MeasurementInputDiscountRateMember2024-03-310000863894srt:MaximumMemberveru:MeasurementInputProbabilityOfChangeOfControlMember2024-03-310000863894srt:MaximumMemberus-gaap:MeasurementInputDiscountRateMember2024-03-310000863894srt:MinimumMemberveru:MeasurementInputProbabilityOfChangeOfControlMember2023-09-300000863894srt:MinimumMemberus-gaap:MeasurementInputDiscountRateMember2023-09-300000863894srt:MaximumMemberveru:MeasurementInputProbabilityOfChangeOfControlMember2023-09-300000863894srt:MaximumMemberus-gaap:MeasurementInputDiscountRateMember2023-09-300000863894srt:ScenarioPreviouslyReportedMember2023-01-012023-03-310000863894srt:RestatementAdjustmentMember2023-01-012023-03-310000863894srt:ScenarioPreviouslyReportedMember2022-10-012023-03-310000863894srt:RestatementAdjustmentMember2022-10-012023-03-310000863894veru:EntadfiMember2023-10-012024-03-310000863894veru:EntadfiMember2022-10-012023-09-300000863894veru:EntadfiMember2023-04-190000863894veru:EquipmentFurnitureAndLeaseholdImprovementsMember2024-03-310000863894veru:EquipmentFurnitureAndLeaseholdImprovementsMember2023-09-300000863894veru:LincolnParkPurchaseAgreementMember2024-03-310000863894veru:JefferiesSalesAgreementMember2024-03-310000863894veru:LincolnParkPurchaseAgreementMember2023-09-300000863894veru:JefferiesSalesAgreementMember2023-09-300000863894veru:JefferiesSalesAgreementMember2023-05-120000863894veru:LincolnParkPurchaseAgreementMember2023-05-020000863894veru:SwkCreditAgreementMember2024-03-310000863894veru:PremiumFinanceAgreementMember2022-11-010000863894veru:ResidualRoyaltyAgreementMember2024-03-310000863894veru:ResidualRoyaltyAgreementMember2023-09-300000863894veru:FiveCustomersMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-03-310000863894veru:TwoCustomersMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-10-012024-03-310000863894veru:FiveCustomersMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-10-012024-03-310000863894veru:TwoCustomersMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-03-310000863894veru:PillClubMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-03-310000863894veru:ThreeCustomersMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2022-10-012023-09-300000863894veru:ThreeCustomersMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-10-012023-03-310000863894veru:PillClubMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-10-012023-03-310000863894srt:MinimumMemberveru:LincolnParkPurchaseAgreementMember2023-12-130000863894srt:ScenarioPreviouslyReportedMember2023-03-310000863894srt:RestatementAdjustmentMember2023-03-310000863894veru:PillClubMember2023-10-012024-03-3100008638942023-03-3100008638942022-09-300000863894us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-03-310000863894us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-03-310000863894us-gaap:EmployeeStockOptionMember2024-01-012024-03-310000863894us-gaap:CostOfSalesMember2024-01-012024-03-310000863894us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-10-012024-03-310000863894us-gaap:ResearchAndDevelopmentExpenseMember2023-10-012024-03-310000863894us-gaap:EmployeeStockOptionMember2023-10-012024-03-310000863894us-gaap:CostOfSalesMember2023-10-012024-03-310000863894us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-03-310000863894us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-310000863894us-gaap:EmployeeStockOptionMember2023-01-012023-03-310000863894us-gaap:CostOfSalesMember2023-01-012023-03-310000863894us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-10-012023-03-310000863894us-gaap:ResearchAndDevelopmentExpenseMember2022-10-012023-03-310000863894us-gaap:EmployeeStockOptionMember2022-10-012023-03-310000863894us-gaap:CostOfSalesMember2022-10-012023-03-3100008638942022-10-012023-03-310000863894us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-3100008638942024-01-012024-03-310000863894veru:LincolnParkPurchaseAgreementMember2023-10-012024-03-310000863894us-gaap:AdditionalPaidInCapitalMember2023-10-012023-12-3100008638942023-10-012023-12-310000863894us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-3100008638942023-01-012023-03-310000863894country:BR2024-03-310000863894veru:CommercialDisputeMember2024-03-310000863894veru:PayableUponExecutionOfAgreementMemberveru:CommercialDisputeMember2024-02-290000863894veru:PayableOnOrPriorToDecember312025Memberveru:CommercialDisputeMember2024-02-290000863894veru:PayableInEqualMonthlyInstallmentsOver48MonthsMemberveru:CommercialDisputeMember2024-02-290000863894veru:CommercialDisputeMember2024-02-2900008638942024-03-3100008638942023-09-3000008638942024-05-0600008638942023-10-012024-03-31veru:customerutr:Yveru:itemxbrli:pureiso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2024

¨

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from              to             

Commission File Number 1-13602

Veru Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Wisconsin

 

39-1144397

(State of Incorporation)

 

(I.R.S. Employer Identification No.)

 

 

2916 N. Miami Avenue, Suite 1000, Miami, FL

 

33127

(Address of Principal Executive Offices)

 

(Zip Code)

305-509-6897

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.01 par value per share

VERU

Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x     No  ¨

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  x     No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ¨

Accelerated filer ¨

Non-accelerated filer x

Smaller reporting companyx

Emerging growth company¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as determined by Rule 12b-2 of the Exchange Act).    Yes  ¨     No  x

As of May 6, 2024, the registrant had 146,383,920 shares of $0.01 par value common stock outstanding.

FORWARD LOOKING STATEMENTS

Certain statements included in this quarterly report on Form 10-Q which are not statements of historical fact are intended to be, and are hereby identified as, “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about our financial condition or business, our development and commercialization plans relating to our product candidates and products, including any potential development or commercialization of enobosarm initially as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a glucagon-like peptide-1 receptor agonist (“GLP-1 RA”) who are at-risk for developing muscle atrophy and muscle weakness, enobosarm for certain breast cancer patients, and sabizabulin for viral-induced acute respiratory distress syndrome (“ARDS”) indications, the outlook for growth in our FC2 business through telehealth customers, our portal and the global public health sector, future financial and operating results, plans, objectives, expectations and intentions, costs and expenses, royalty payments, outcome of litigation and other contingencies, financial condition, results of operations, liquidity, cost savings, our ability to continue as a going concern, future ordering patterns of our customers, objectives of management, business strategies, clinical trial timing, plans and results, the achievement of clinical and commercial milestones, the advancement of our technologies and our products and drug candidates, and other statements that are not historical facts. Forward-looking statements can be identified by the use of forward-looking words or phrases such as “anticipate,” “believe,” “could,” “expect,” “intend,” “may,” “opportunity,” “plan,” “predict,” “potential,” “estimate,” “should,” “will,” “would” or the negative of these terms or other words of similar meaning. These statements are based upon the Company’s current plans and strategies and reflect the Company’s current assessment of the risks and uncertainties related to its business and are made as of the date of this report. These statements are inherently subject to known and unknown risks and uncertainties. You should read these statements carefully because they discuss our future expectations or state other “forward-looking” information. There may be events in the future that we are not able to accurately predict or control and our actual results may differ materially from the expectations we describe in our forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include the following:

potential delays in the timing of and results from clinical trials and studies, including potential delays in the recruitment of patients and their ability to effectively participate in such trials and studies, and the risk that such results will not support marketing approval, emergency use authorization (“EUA”), or commercialization in the United States or in any foreign country;

potential delays in the timing of any submission to the U.S. Food and Drug Administration (the “FDA”) or any other regulatory authority around the world and potential delays in, or failure to obtain, from any such regulatory authority approval of products under development, including the risk of a delay or failure in reaching agreement with the FDA on the design of any clinical trial, including any post-approval or post-authorization study, or in obtaining authorization to commence a clinical trial or commercialize a product candidate in the U.S. or elsewhere;

potential delays in the timing of approval by the FDA or any other regulatory authority of the release of manufactured lots of approved products;

clinical trial results supporting any potential regulatory approval or authorization of any of our products, including enobosarm initially as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness, enobosarm for breast cancer, and sabizabulin for the treatment of viral-induced ARDS, may not be replicated in clinical practice;

clinical results or early data from clinical trials may not be replicated or continue to occur in additional trials or may not otherwise support further development in the specified product candidate or at all;

risks related to our ability to obtain sufficient financing on acceptable terms when needed to fund product development and our operations and to enable us to continue as a going concern;

as a result of our failure to timely file two reports with the Securities and Exchange Commission we are not eligible to file new registration statements on Form S-3 until no earlier than March 1, 2025 and, while we believe we may currently use our current effective shelf registration statement on Form S-3 to a certain extent, we will no longer be able to use our current effective shelf registration statement on Form S-3 between the time we file our Annual Report on Form 10-K for the year ending September 30, 2024 and at least March 1, 2025, which could impair our capital-raising activities (see Part II, Item 1A, “Risk Factors”);

we need to secure significant funding to advance our drug candidates, including government grants, pharmaceutical company partnerships, or similar external sources to advance the development of sabizabulin as a treatment for viral-induced ARDS;

we may not receive any additional payments from Onconetix, Inc. formerly known as Blue Water Vaccines Inc. (“BWV”) in connection with the sale of our ENTADFI assets and may not receive any value for the shares of Series A Convertible Preferred Stock of BWV we hold;

risks related to the development of our product portfolio, including clinical trials, regulatory approvals and time and cost to bring any of our product candidates to market, and risks related to efforts of our collaborators;

product demand and market acceptance of our commercial products and our products in development, if approved;

risks related to our ability to obtain insurance reimbursement from private payors or government payors, including Medicare and Medicaid, and similar risks relating to market or political acceptance of any potential or actual pricing for any of our product candidates that, if approved, we attempt to commercialize;

some of our products are in development and we may fail to successfully commercialize such products;

risks related to our current and any potential new telehealth platform developed or used by us in commercializing our current product or potential future products, including potential regulatory uncertainty around such platforms and market awareness and acceptance of any telehealth platform we develop or use;

risks related to our ability to increase sales of FC2 after significant declines in recent periods due to telehealth industry consolidation and the bankruptcy of large telehealth customers;

risks related to intellectual property, including the uncertainty of obtaining intellectual property protections and in enforcing them, the possibility of infringing a third party’s intellectual property, and licensing risks;

competition from existing and new competitors including the potential for reduced sales, pressure on pricing and increased spending on marketing;

risks related to compliance and regulatory matters, including costs and delays resulting from extensive government regulation and reimbursement and coverage under healthcare insurance and regulation as well as potential healthcare reform measures;

the risk that we will be affected by regulatory and legal developments, including a reclassification of products or repeal or modification of part or all of the Patient Protection and Affordable Care Act;

risks inherent in doing business on an international level, including currency risks, regulatory requirements, political risks, export restrictions and other trade barriers;

the disruption of production at our manufacturing facilities or facilities of third parties on which we rely and/or of our ability to supply product due to raw material shortages, labor shortages, manufacturing partner business changes, physical damage to our or third parties’ facilities, product testing, transportation delays or regulatory or other governmental actions, and the duration and impact of any such disruptions;

our reliance on major customers and risks related to delays in, or failure to make, payment of accounts receivable by major customers;

risks from rising costs of raw materials and our ability to pass along increased costs to our customers;

risks related to our growth strategy;

our continued ability to attract and retain highly skilled and qualified personnel;

risks relating to the restatement of our unaudited condensed consolidated financial statements as of and for the three and nine months ended June 30, 2023 and the restatement of our audited consolidated financial statements as of and for the years ended September 30, 2023 and 2022;

the costs and other effects of litigation, governmental investigations, legal and administrative cases and proceedings, settlements and investigations;

our ability to remediate the material weaknesses in our internal control over financial reporting that we have identified and the risk that we identify additional deficiencies in our internal control over financial reporting or otherwise fail to maintain an effective system of internal controls;

government contracting risks, including the appropriations process and funding priorities, potential bureaucratic delays in awarding contracts, process errors, politics or other pressures, and the risk that government tenders and contracts may be subject to cancellation, delay, restructuring or substantial delayed payments;

a governmental tender award indicates acceptance of the bidder’s price rather than an order or guarantee of the purchase of any minimum number of units, and as a result government ministries or other public health sector customers may order and purchase fewer units than the full maximum tender amount;

our ability to identify, successfully negotiate and complete suitable acquisitions, out-licensing transactions, in-licensing transactions or other strategic initiatives and to realize any potential benefits of such transactions or initiatives; and

our ability to successfully integrate acquired businesses, technologies or products.

All forward-looking statements in this report should be considered in the context of the risks and other factors described above, in Part II, Item 1A, “Risk Factors” below in this report, and in Part I, Item 1A, “Risk Factors,” in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2023, as amended by Amendment No. 1 to the Company’s Annual Report on Form 10-K/A as filed with the Securities and Exchange Commission on April 1, 2024 (references in this report to the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2023 include such Amendment No. 1). The Company undertakes no obligation to make any revisions to the forward-looking statements contained in this report or to update them to reflect events or circumstances occurring after the date of this report except as required by applicable law.

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

VERU INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

March 31,

September 30,

2024

2023 (Restated)

Assets

Current assets:

Cash and cash equivalents

$

34,738,038

$

9,625,494 

Accounts receivable, net

2,785,331

4,506,508 

Inventories, net

4,804,665

6,697,117 

Prepaid research and development costs

924,583

1,006,252 

Prepaid expenses and other current assets

1,884,684

1,097,851 

Total current assets

45,137,301

22,933,222 

Plant and equipment, net

1,534,196

1,652,732 

Operating lease right-of-use assets

3,947,417

4,332,473 

Investments in equity securities

346,444

Deferred income taxes

12,635,927

12,707,419 

Goodwill

6,878,932 

6,878,932 

Other assets

1,320,142

1,518,313 

Total assets

$

71,800,359

$

50,023,091 

Liabilities and Stockholders' Equity

Current liabilities:

Accounts payable

$

2,464,135

$

12,931,172 

Accrued compensation

2,683,214

990,609 

Accrued expenses and other current liabilities

2,425,385

1,987,738

Residual royalty agreement liability, short-term portion

950,600

864,623 

Operating lease liability, short-term portion

1,043,029

1,036,590 

Total current liabilities

9,566,363

17,810,732

Residual royalty agreement liability, long-term portion

8,775,284

8,870,136 

Operating lease liability, long-term portion

3,262,818

3,634,114 

Other liabilities

4,986,250

29,948 

Total liabilities

26,590,715

30,344,930

Commitments and contingencies (Note 12)

 

 

Stockholders' equity:

Preferred stock; no shares issued and outstanding at March 31, 2024 and September 30, 2023

Common stock, par value $0.01 per share; 308,000,000 shares authorized, 148,564,890 and 93,966,402 shares issued and 146,381,186 and 91,782,698 shares outstanding at March 31, 2024 and September 30, 2023, respectively

1,485,649 

939,664 

Additional paid-in-capital

327,182,257

283,894,830 

Accumulated other comprehensive loss

(581,519)

(581,519)

Accumulated deficit

(275,070,138)

(256,768,209)

Treasury stock, 2,183,704 shares, at cost

(7,806,605)

(7,806,605)

Total stockholders' equity

45,209,644

19,678,161

Total liabilities and stockholders' equity

$

71,800,359

$

50,023,091 

See notes to unaudited condensed consolidated financial statements.

 

VERU INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

Three Months Ended

Six Months Ended

March 31,

March 31,

2024

2023 (Restated)

2024

2023 (Restated)

Net revenues

$

4,135,301

$

6,585,967

$

6,276,027

$

9,093,761

 

Cost of sales

3,457,002

2,493,892

4,447,276

4,299,631

 

Gross profit

678,299

4,092,075

1,828,751

4,794,130

 

Operating expenses:

Research and development

2,986,791

17,860,701

4,636,841

38,471,828

Selling, general and administrative

7,580,340

12,834,494

15,881,771

30,380,359

Provision for credit losses

3,911,714

3,911,714

Impairment of intangible assets

3,900,000

3,900,000

Total operating expenses

10,567,131

38,506,909

20,518,612

76,663,901

Gain on sale of ENTADFI® assets

918,372

Operating loss

(9,888,832)

(34,414,834)

(17,771,489)

(71,869,771)

 

Non-operating income (expenses):

Interest expense

(145,310)

(697,693)

(310,267)

(1,570,923)

Change in fair value of derivative liabilities

21,000

1,200,000

19,000

530,000

Change in fair value of equity securities

(192,030)

(571,928)

Other income, net

361,226

56,994

442,318

277,926

Total non-operating income (expenses)

44,886

559,301

(420,877)

(762,997)

 

Loss before income taxes

(9,843,946)

(33,855,533)

(18,192,366)

(72,632,768)

 

Income tax expense (benefit)

182,002

(66,559)

109,563

(134,837)

Net loss

$

(10,025,948)

$

(33,788,974)

$

(18,301,929)

$

(72,497,931)

 

Net loss per basic and diluted common shares outstanding

$

(0.07)

$

(0.42)

$

(0.15)

$

(0.90)

 

Basic and diluted weighted average common shares outstanding

146,381,186

80,834,453

123,366,486

80,695,046

 

See notes to unaudited condensed consolidated financial statements.

 

VERU INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

 

Accumulated

 

Additional

Other

Treasury

 

Common Stock

Paid-in

Comprehensive

Accumulated

Stock,

 

Shares

Amount

Capital

Loss

Deficit

at Cost

Total

 

Balance at September 30, 2023 (Restated)

93,966,402

$

939,664

$

283,894,830

$

(581,519)

$

(256,768,209)

$

(7,806,605)

$

19,678,161

Share-based compensation

3,406,949

3,406,949

Issuance of shares pursuant to Jefferies Sales Agreement, net of commissions and costs

90,156

902

65,649

66,551

Shares issued in connection with common stock purchase agreement

1,800,000

18,000

1,643,490

1,661,490

Amortization of deferred costs

(164,313)

(164,313)

Shares issued in connection with public offering of common stock, net of fees and costs

52,708,332

527,083

34,702,332

35,229,415

Net loss

(8,275,981)

(8,275,981)

Balance at December 31, 2023

148,564,890

1,485,649

323,548,937

(581,519)

(265,044,190)

(7,806,605)

51,602,272

Share-based compensation

3,634,171

3,634,171

Costs of shares issued in connection with common stock purchase agreement

(851)

(851)

Net loss

(10,025,948)

(10,025,948)

Balance at March 31, 2024

148,564,890

$

1,485,649

$

327,182,257

$

(581,519)

$

(275,070,138)

$

(7,806,605)

$

45,209,644

 

Balance at September 30, 2022 (Restated)

82,692,598

$

826,926

$

253,974,032

$

(581,519)

$

(163,615,517)

$

(7,806,605)

$

82,797,317

Share-based compensation

4,845,269

4,845,269

Issuance of shares pursuant to share-based awards

114,234

1,142

255,990